Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long term lenalidomide therapy: incidence and prognostic significance.

08:00 EDT 23rd April 2013 | BioPortfolio

Summary of "Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long term lenalidomide therapy: incidence and prognostic significance."

No Summary Available


Department of Medicine, Division of Hematologic Malignancies.

Journal Details

This article was published in the following journal.

Name: Leukemia
ISSN: 1476-5551


PubMed Articles [41519 Associated PubMed Articles listed on BioPortfolio]

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA ...

Smoldering Multiple Myeloma: Pathophysiologic Insights, Novel Diagnostics, Clinical Risk Models, and Treatment Strategies.

Smoldering multiple myeloma (SMM) is a plasma cell disorder first described in 1980 when 6 patients were observed to meet the diagnostic criteria of multiple myeloma, defined as bone marrow plasmacyto...

Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma.

CD20 expression was reported at different rates in patients with multiple myeloma. The importance of this B-cell antigen for plasma cells is still unknown. This study aimed to investigate CD20 express...

Correlation of WT1 and VEGF Expression with Angiogenesis in Bone Marrow Biopsies of Multiple Myeloma Patients.

To investigate the relationship of WT1 and VEGF expression with angiogenesis in bone marrow biopsies of multiple myeloma patients.

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.

Alterations and senescence in bone marrow mesenchymal stromal cells of multiple myeloma patients (MM-BMMSCs) have become an important research focus. However the role of senescence in the pathophysiol...

Clinical Trials [5693 Associated Clinical Trials listed on BioPortfolio]

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. ...

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation. PURPOSE: This phase II...

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

The primary objective is to cure multiple myeloma with less toxic allogeneic bone marrow transplantation while inducing renal allograft tolerance through mixed chimerism in patients with e...

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell...

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions ev...

Medical and Biotech [MESH] Definitions

Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.

Multiple protein bands serving as markers of specific ANTIBODIES and detected by ELECTROPHORESIS of CEREBROSPINAL FLUID or serum. The bands are most often seen during inflammatory or immune processes and are found in most patients with MULTIPLE SCLEROSIS.


Searches Linking to this Article